Anandamide

Anandamide is a lipid of Fatty Acyls (FA) class. Anandamide is associated with abnormalities such as Dehydration. The involved functions are known as Process, Phenomenon, Phosphorylation, Catabolic Process and Gene Expression. Anandamide often locates in Nuchal region, Microglial and Hepatic. The associated genes with Anandamide are SGPL1 gene, SPTLC1 gene, RPSA gene, KDSR gene and SMPD1 gene. The related lipids are Sphingolipids, Lipopolysaccharides, Lysophospholipids, LYSO-PC and lysophosphatidylethanolamine.

Cross Reference

Introduction

To understand associated biological information of Anandamide, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Anandamide?

Anandamide is suspected in Dehydration and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Anandamide

MeSH term MeSH ID Detail
Alzheimer Disease D000544 76 associated lipids
Anorexia D000855 8 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Ataxia D001259 20 associated lipids
Urinary Bladder Diseases D001745 4 associated lipids
Body Weight D001835 333 associated lipids
Bradycardia D001919 13 associated lipids
Brain Concussion D001924 5 associated lipids
Brain Damage, Chronic D001925 6 associated lipids
Brain Edema D001929 20 associated lipids
Breast Neoplasms D001943 24 associated lipids
Bronchial Spasm D001986 18 associated lipids
Bulimia D002032 3 associated lipids
Cardiomyopathy, Dilated D002311 15 associated lipids
Catalepsy D002375 30 associated lipids
Celiac Disease D002446 16 associated lipids
Brain Ischemia D002545 89 associated lipids
Ischemic Attack, Transient D002546 42 associated lipids
Colitis D003092 69 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Cough D003371 19 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Diabetic Retinopathy D003930 39 associated lipids
Dyskinesia, Drug-Induced D004409 15 associated lipids
Edema D004487 152 associated lipids
Encephalomyelitis, Autoimmune, Experimental D004681 26 associated lipids
Epilepsy D004827 35 associated lipids
Fatty Liver D005234 48 associated lipids
Fever D005334 35 associated lipids
Fibromyalgia D005356 4 associated lipids
Glioma D005910 112 associated lipids
Hepatitis D006505 11 associated lipids
Hyperalgesia D006930 42 associated lipids
Hyperemia D006940 25 associated lipids
Hyperinsulinism D006946 27 associated lipids
Hyperkinesis D006948 11 associated lipids
Hypersensitivity, Delayed D006968 43 associated lipids
Hypertension D006973 115 associated lipids
Hypertension, Portal D006975 12 associated lipids
Hypotension D007022 41 associated lipids
Hypothermia D007035 19 associated lipids
Inflammation D007249 119 associated lipids
Insulin Resistance D007333 99 associated lipids
Intestinal Pseudo-Obstruction D007418 5 associated lipids
Learning Disorders D007859 11 associated lipids
Liver Cirrhosis D008103 67 associated lipids
Melanoma D008545 69 associated lipids
Memory Disorders D008569 33 associated lipids
Migraine Disorders D008881 11 associated lipids
Morphine Dependence D009021 9 associated lipids
Multiple Sclerosis D009103 13 associated lipids
Muscle Spasticity D009128 5 associated lipids
Mycoses D009181 18 associated lipids
Neoplasm Invasiveness D009361 23 associated lipids
Neoplasms D009369 13 associated lipids
Neovascularization, Pathologic D009389 39 associated lipids
Nerve Degeneration D009410 53 associated lipids
Nervous System Diseases D009422 37 associated lipids
Neuralgia D009437 28 associated lipids
Neuroblastoma D009447 66 associated lipids
Obesity D009765 29 associated lipids
Pain D010146 64 associated lipids
Parkinson Disease, Secondary D010302 17 associated lipids
Peptic Ulcer D010437 19 associated lipids
Peripheral Nervous System Diseases D010523 33 associated lipids
Picornaviridae Infections D010850 4 associated lipids
Pregnancy, Ectopic D011271 5 associated lipids
Prostatic Neoplasms D011471 126 associated lipids
Schistosomiasis japonica D012554 3 associated lipids
Seizures D012640 87 associated lipids
Shock, Septic D012772 11 associated lipids
Sleep Deprivation D012892 5 associated lipids
Spinal Cord Injuries D013119 34 associated lipids
Stomach Ulcer D013276 75 associated lipids
Thyroid Neoplasms D013964 33 associated lipids
Urinary Incontinence D014549 4 associated lipids
Ventricular Fibrillation D014693 16 associated lipids
Reperfusion Injury D015427 65 associated lipids
Weight Gain D015430 101 associated lipids
Ocular Hypotension D015814 2 associated lipids
Alveolar Bone Loss D016301 10 associated lipids
Cardiovirus Infections D018188 3 associated lipids
Cholangiocarcinoma D018281 7 associated lipids
Ventricular Dysfunction, Left D018487 33 associated lipids
Impotence, Vasculogenic D018783 4 associated lipids
Pancreatitis, Acute Necrotizing D019283 18 associated lipids
Endotoxemia D019446 27 associated lipids
Neurodegenerative Diseases D019636 32 associated lipids
Substance-Related Disorders D019966 2 associated lipids
Sleep Apnea, Obstructive D020181 9 associated lipids
Infarction, Middle Cerebral Artery D020244 35 associated lipids
Amnesia, Anterograde D020324 2 associated lipids
Osteoarthritis, Knee D020370 13 associated lipids
Sciatic Neuropathy D020426 13 associated lipids
Parkinsonian Disorders D020734 20 associated lipids
Somatosensory Disorders D020886 1 associated lipids
Sleep Disorders, Intrinsic D020919 1 associated lipids
Hypoxia-Ischemia, Brain D020925 22 associated lipids
Per page 10 20 50 100 | Total 105

PubChem Associated disorders and diseases

What pathways are associated with Anandamide

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Anandamide?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Anandamide?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Anandamide?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Anandamide?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Anandamide?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with Anandamide

Download all related citations
Per page 10 20 50 100 | Total 2222
Authors Title Published Journal PubMed Link
Rajesh M et al. Cannabinoid 1 receptor promotes cardiac dysfunction, oxidative stress, inflammation, and fibrosis in diabetic cardiomyopathy. 2012 Diabetes pmid:22315315
Troy-Fioramonti S et al. Acute activation of cannabinoid receptors by anandamide reduces gastrointestinal motility and improves postprandial glycemia in mice. 2015 Diabetes pmid:25281429
Engeli S et al. Activation of the peripheral endocannabinoid system in human obesity. 2005 Diabetes pmid:16186383
Mallat A and Lotersztajn S Cannabinoid receptors as novel therapeutic targets for the management of non-alcoholic steatohepatitis. 2008 Diabetes Metab. pmid:19195630
Eckardt K et al. Cannabinoid type 1 receptors in human skeletal muscle cells participate in the negative crosstalk between fat and muscle. 2009 Diabetologia pmid:19089403
Harada N and Okajima K Inhibition of neutrophil activation by lafutidine, an H2-receptor antagonist, through enhancement of sensory neuron activation contributes to the reduction of stress-induced gastric mucosal injury in rats. 2007 Dig. Dis. Sci. pmid:17211693
González S et al. Behavioral and molecular changes elicited by acute administration of SR141716 to Delta9-tetrahydrocannabinol-tolerant rats: an experimental model of cannabinoid abstinence. 2004 Drug Alcohol Depend pmid:15099659
Childers SR and Breivogel CS Cannabis and endogenous cannabinoid systems. 1998 Jun-Jul Drug Alcohol Depend pmid:9716939
Welch SP Characterization of anandamide-induced tolerance: comparison to delta 9-THC-induced interactions with dynorphinergic systems. 1997 Drug Alcohol Depend pmid:9179505
Muccioli GG Endocannabinoid biosynthesis and inactivation, from simple to complex. 2010 Drug Discov. Today pmid:20304091
Farrell EK and Merkler DJ Biosynthesis, degradation and pharmacological importance of the fatty acid amides. 2008 Drug Discov. Today pmid:18598910
Sridar C et al. Anandamide oxidation by wild-type and polymorphically expressed CYP2B6 and CYP2D6. 2011 Drug Metab. Dispos. pmid:21289075
Pratt-Hyatt M et al. Effects of a commonly occurring genetic polymorphism of human CYP3A4 (I118V) on the metabolism of anandamide. 2010 Drug Metab. Dispos. pmid:20702771
Ekins S et al. Three-dimensional quantitative structure-activity relationship analysis of human CYP51 inhibitors. 2007 Drug Metab. Dispos. pmid:17194716
Jia Y et al. TRPV1 receptor: a target for the treatment of pain, cough, airway disease and urinary incontinence. 2005 Drug News Perspect. pmid:15915217
Thieme U et al. Quantification of anandamide and 2-arachidonoylglycerol plasma levels to examine potential influences of tetrahydrocannabinol application on the endocannabinoid system in humans. 2014 Jan-Feb Drug Test Anal pmid:24424856
Battista N et al. Analytical approaches for the determination of phytocannabinoids and endocannabinoids in human matrices. 2014 Jan-Feb Drug Test Anal pmid:24218186
Maingret F et al. The endocannabinoid anandamide is a direct and selective blocker of the background K(+) channel TASK-1. 2001 EMBO J. pmid:11226154
Chemin J et al. Direct inhibition of T-type calcium channels by the endogenous cannabinoid anandamide. 2001 EMBO J. pmid:11742980
van der Stelt M et al. Anandamide acts as an intracellular messenger amplifying Ca2+ influx via TRPV1 channels. 2005 EMBO J. pmid:16107881
Laezza C et al. Inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity and of Ras farnesylation mediate antitumor effects of anandamide in human breast cancer cells. 2010 Endocr. Relat. Cancer pmid:20304978
Karlsson C et al. Baseline anandamide levels and body weight impact the weight loss effect of CB1 receptor antagonism in male rats. 2015 Endocrinology pmid:25549047
Francavilla F et al. Characterization of the endocannabinoid system in human spermatozoa and involvement of transient receptor potential vanilloid 1 receptor in their fertilizing ability. 2009 Endocrinology pmid:19608651
Forner-Piquer I et al. Dose-Specific Effects of Di-Isononyl Phthalate on the Endocannabinoid System and on Liver of Female Zebrafish. 2017 Endocrinology pmid:28938452
Maccarrone M et al. Anandamide activity and degradation are regulated by early postnatal aging and follicle-stimulating hormone in mouse Sertoli cells. 2003 Endocrinology pmid:12488326
Rossi G et al. Follicle-stimulating hormone activates fatty acid amide hydrolase by protein kinase A and aromatase-dependent pathways in mouse primary Sertoli cells. 2007 Endocrinology pmid:17110429
Martella A et al. Bisphenol A Induces Fatty Liver by an Endocannabinoid-Mediated Positive Feedback Loop. 2016 Endocrinology pmid:27014939
Melck D et al. Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. 2000 Endocrinology pmid:10614630
Habayeb OM et al. Expression of the endocannabinoid system in human first trimester placenta and its role in trophoblast proliferation. 2008 Endocrinology pmid:18599552
Romigi A et al. Cerebrospinal fluid levels of the endocannabinoid anandamide are reduced in patients with untreated newly diagnosed temporal lobe epilepsy. 2010 Epilepsia pmid:19817812
Manna SS and Umathe SN Involvement of transient receptor potential vanilloid type 1 channels in the pro-convulsant effect of anandamide in pentylenetetrazole-induced seizures. 2012 Epilepsy Res. pmid:22386872
Citraro R et al. CB1 agonists, locally applied to the cortico-thalamic circuit of rats with genetic absence epilepsy, reduce epileptic manifestations. 2013 Epilepsy Res. pmid:23860329
Schaefer C et al. Fatty acid ethanolamide levels are altered in borderline personality and complex posttraumatic stress disorders. 2014 Eur Arch Psychiatry Clin Neurosci pmid:24253425
Moloney GP et al. Synthesis and cannabinoid activity of 1-substituted-indole-3-oxadiazole derivatives: novel agonists for the CB1 receptor. 2008 Eur J Med Chem pmid:17582659
Ortar G et al. Carbamoyl tetrazoles as inhibitors of endocannabinoid inactivation: a critical revisitation. 2008 Eur J Med Chem pmid:17452063
López-Rodríguez ML et al. Design, synthesis and biological evaluation of new endocannabinoid transporter inhibitors. 2003 Eur J Med Chem pmid:12750028
Bonechi C et al. Nuclear magnetic resonance for studying recognition processes between anandamide and cannabinoid receptors. 2006 Eur J Med Chem pmid:16837109
Cano C et al. Synthesis and pharmacological evaluation of sulfamide-based analogues of anandamide. 2009 Eur J Med Chem pmid:19762126
Monteleone AM et al. Responses of peripheral endocannabinoids and endocannabinoid-related compounds to hedonic eating in obesity. 2016 Eur J Nutr pmid:26759262
Ford GK et al. Involvement of the endocannabinoid system in attentional modulation of nociceptive behaviour in rats. 2015 Eur J Pain pmid:25504741
Juntunen J et al. Anandamide prodrugs. 1. Water-soluble phosphate esters of arachidonylethanolamide and R-methanandamide. 2003 Eur J Pharm Sci pmid:12729860
Karlsson M et al. Reversible, temperature-dependent, and AM404-inhibitable adsorption of anandamide to cell culture wells as a confounding factor in release experiments. 2004 Eur J Pharm Sci pmid:15158903
McLaughlin RJ et al. Prefrontal cortical anandamide signaling coordinates coping responses to stress through a serotonergic pathway. 2012 Eur Neuropsychopharmacol pmid:22325231
Manduca A et al. Distinct roles of the endocannabinoids anandamide and 2-arachidonoylglycerol in social behavior and emotionality at different developmental ages in rats. 2015 Eur Neuropsychopharmacol pmid:25914159
de Lago E et al. UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders. 2006 Eur Neuropsychopharmacol pmid:16006105
Ellgren M et al. Dynamic changes of the endogenous cannabinoid and opioid mesocorticolimbic systems during adolescence: THC effects. 2008 Eur Neuropsychopharmacol pmid:18674887
Kaufmann I et al. Enhanced anandamide plasma levels in patients with complex regional pain syndrome following traumatic injury: a preliminary report. 2009 Eur Surg Res pmid:19729930
Quercioli A et al. Elevated endocannabinoid plasma levels are associated with coronary circulatory dysfunction in obesity. 2011 Eur. Heart J. pmid:21303779
Raichlen DA et al. Exercise-induced endocannabinoid signaling is modulated by intensity. 2013 Eur. J. Appl. Physiol. pmid:22990628
Feuerecker M et al. Effects of exercise stress on the endocannabinoid system in humans under field conditions. 2012 Eur. J. Appl. Physiol. pmid:22101870
Bisogno T et al. Biosynthesis and degradation of bioactive fatty acid amides in human breast cancer and rat pheochromocytoma cells--implications for cell proliferation and differentiation. 1998 Eur. J. Biochem. pmid:9688276
Van Der Stelt M and Di Marzo V Endovanilloids. Putative endogenous ligands of transient receptor potential vanilloid 1 channels. 2004 Eur. J. Biochem. pmid:15128293
MacCarrone M et al. Human platelets bind and degrade 2-arachidonoylglycerol, which activates these cells through a cannabinoid receptor. 2001 Eur. J. Biochem. pmid:11168423
Fasia L et al. Uptake and metabolism of [3H]anandamide by rabbit platelets. Lack of transporter? 2003 Eur. J. Biochem. pmid:12919314
Bisogno T et al. The uptake by cells of 2-arachidonoylglycerol, an endogenous agonist of cannabinoid receptors. 2001 Eur. J. Biochem. pmid:11277920
Salzet M et al. Comparative biology of the endocannabinoid system possible role in the immune response. 2000 Eur. J. Biochem. pmid:10931174
Sugiura T et al. Transacylase-mediated and phosphodiesterase-mediated synthesis of N-arachidonoylethanolamine, an endogenous cannabinoid-receptor ligand, in rat brain microsomes. Comparison with synthesis from free arachidonic acid and ethanolamine. 1996 Eur. J. Biochem. pmid:8797835
Matias I et al. Presence and regulation of the endocannabinoid system in human dendritic cells. 2002 Eur. J. Biochem. pmid:12153574
Kapoor S Modulation of intracellular pathways by anandamide and its evolving role in oncology. 2013 Eur. J. Cancer pmid:23434147
Laezza C et al. Anandamide inhibits the Wnt/β-catenin signalling pathway in human breast cancer MDA MB 231 cells. 2013 Eur. J. Cancer pmid:23434151
Rossi C et al. Endocannabinoids in platelets of chronic migraine patients and medication-overuse headache patients: relation with serotonin levels. 2008 Eur. J. Clin. Pharmacol. pmid:18004553
Di Marzo V et al. Role of insulin as a negative regulator of plasma endocannabinoid levels in obese and nonobese subjects. 2009 Eur. J. Endocrinol. pmid:19745037
Adermark L et al. Endocannabinoid-dependent plasticity at GABAergic and glutamatergic synapses in the striatum is regulated by synaptic activity. 2009 Eur. J. Neurosci. pmid:19120438
Millns PJ et al. Effects of inhibition of fatty acid amide hydrolase vs. the anandamide membrane transporter on TRPV1-mediated calcium responses in adult DRG neurons; the role of CB receptors. 2006 Eur. J. Neurosci. pmid:17229097
Sharkey KA et al. Arvanil, anandamide and N-arachidonoyl-dopamine (NADA) inhibit emesis through cannabinoid CB1 and vanilloid TRPV1 receptors in the ferret. 2007 Eur. J. Neurosci. pmid:17459108
Ryan D et al. Interactions of cannabidiol with endocannabinoid signalling in hippocampal tissue. 2007 Eur. J. Neurosci. pmid:17419758
Ahluwalia J et al. Anandamide regulates neuropeptide release from capsaicin-sensitive primary sensory neurons by activating both the cannabinoid 1 receptor and the vanilloid receptor 1 in vitro. 2003 Eur. J. Neurosci. pmid:12823468
Sagan S et al. Anandamide and WIN 55212-2 inhibit cyclic AMP formation through G-protein-coupled receptors distinct from CB1 cannabinoid receptors in cultured astrocytes. 1999 Eur. J. Neurosci. pmid:10051770
Cippitelli A et al. The anandamide transport inhibitor AM404 reduces ethanol self-administration. 2007 Eur. J. Neurosci. pmid:17650118
Ali AB and Todorova M Asynchronous release of GABA via tonic cannabinoid receptor activation at identified interneuron synapses in rat CA1. 2010 Eur. J. Neurosci. pmid:20345910
Lemak MS et al. Cannabinoid regulation in identified synapse of terrestrial snail. 2007 Eur. J. Neurosci. pmid:18028114
Béquet F et al. CB1 receptor-mediated control of the release of endocannabinoids (as assessed by microdialysis coupled with LC/MS) in the rat hypothalamus. 2007 Eur. J. Neurosci. pmid:18052990
Rivera P et al. Diet-dependent modulation of hippocampal expression of endocannabinoid signaling-related proteins in cannabinoid antagonist-treated obese rats. 2013 Eur. J. Neurosci. pmid:23033907
Sousa-Valente J et al. Anandamide in primary sensory neurons: too much of a good thing? 2014 Eur. J. Neurosci. pmid:24494681
Rea K et al. Microinjection of 2-arachidonoyl glycerol into the rat ventral hippocampus differentially modulates contextually induced fear, depending on a persistent pain state. 2014 Eur. J. Neurosci. pmid:24494683
Maccarrone M et al. Age-related changes of anandamide metabolism in CB1 cannabinoid receptor knockout mice: correlation with behaviour. 2002 Eur. J. Neurosci. pmid:11982628
Holt S et al. Inhibition of fatty acid amide hydrolase, a key endocannabinoid metabolizing enzyme, by analogues of ibuprofen and indomethacin. 2007 Eur. J. Pharmacol. pmid:17397826
Rodella LF et al. AM404, an inhibitor of anandamide reuptake decreases Fos-immunoreactivity in the spinal cord of neuropathic rats after non-noxious stimulation. 2005 Eur. J. Pharmacol. pmid:15680264
Vann RE et al. Discriminative stimulus properties of delta9-tetrahydrocannabinol (THC) in C57Bl/6J mice. 2009 Eur. J. Pharmacol. pmid:19470387
Wallace MJ et al. Evidence for a physiological role of endocannabinoids in the modulation of seizure threshold and severity. 2002 Eur. J. Pharmacol. pmid:12359270
Kelley BG and Thayer SA Anandamide transport inhibitor AM404 and structurally related compounds inhibit synaptic transmission between rat hippocampal neurons in culture independent of cannabinoid CB1 receptors. 2004 Eur. J. Pharmacol. pmid:15288572
O'Sullivan SE et al. Vascular effects of delta 9-tetrahydrocannabinol (THC), anandamide and N-arachidonoyldopamine (NADA) in the rat isolated aorta. 2005 Eur. J. Pharmacol. pmid:15659311
Wheal AJ et al. Hydrogen peroxide as a mediator of vasorelaxation evoked by N-oleoylethanolamine and anandamide in rat small mesenteric arteries. 2012 Eur. J. Pharmacol. pmid:22154756
Bouaboula M et al. Anandamide induced PPARgamma transcriptional activation and 3T3-L1 preadipocyte differentiation. 2005 Eur. J. Pharmacol. pmid:15987634
McQueen DS et al. Cannabidiol lacks the vanilloid VR1-mediated vasorespiratory effects of capsaicin and anandamide in anaesthetised rats. 2004 Eur. J. Pharmacol. pmid:15140635
Fowler CJ et al. Selective inhibition of anandamide cellular uptake versus enzymatic hydrolysis--a difficult issue to handle. 2004 Eur. J. Pharmacol. pmid:15145699
Wiley JL et al. Endocannabinoid contribution to Δ9-tetrahydrocannabinol discrimination in rodents. 2014 Eur. J. Pharmacol. pmid:24858366
Shimasue K et al. Effects of anandamide and arachidonic acid on specific binding of (+) -PN200-110, diltiazem and (-) -desmethoxyverapamil to L-type Ca2+ channel. 1996 Eur. J. Pharmacol. pmid:8904088
García Mdel C et al. Role of CGRP and GABA in the hypotensive effect of intrathecally administered anandamide to anesthetized rats. 2006 Eur. J. Pharmacol. pmid:16472800
Walentiny DM et al. The endogenous cannabinoid anandamide shares discriminative stimulus effects with ∆(9)-tetrahydrocannabinol in fatty acid amide hydrolase knockout mice. 2011 Eur. J. Pharmacol. pmid:21300050
Fride E and Mechoulam R Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent. 1993 Eur. J. Pharmacol. pmid:8384116
Zaniewska M et al. Evaluation of the role of nicotinic acetylcholine receptor subtypes and cannabinoid system in the discriminative stimulus effects of nicotine in rats. 2006 Eur. J. Pharmacol. pmid:16730696
Alptekin A et al. The effects of anandamide transport inhibitor AM404 on voltage-dependent calcium channels. 2010 Eur. J. Pharmacol. pmid:20171208
Begg M et al. Modulation of the release of endogenous gamma-aminobutyric acid by cannabinoids in the guinea pig ileum. 2002 Eur. J. Pharmacol. pmid:11755170
Giuffrida A et al. Elevated circulating levels of anandamide after administration of the transport inhibitor, AM404. 2000 Eur. J. Pharmacol. pmid:11080522
Calignano A et al. Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide. 2001 Eur. J. Pharmacol. pmid:11426841
Fride E et al. Critical role of the endogenous cannabinoid system in mouse pup suckling and growth. 2001 Eur. J. Pharmacol. pmid:11426843
Lay L et al. Pharmacological characterisation of cannabinoid CB(1) receptors in the rat and mouse. 2000 Eur. J. Pharmacol. pmid:10720647
Di Marzo V et al. Neurobehavioral activity in mice of N-vanillyl-arachidonyl-amide. 2000 Eur. J. Pharmacol. pmid:11040343
Rácz I et al. Anandamide effects on 5-HT(3) receptors in vivo. 2008 Eur. J. Pharmacol. pmid:18775693